Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

References

• Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83
   PubMed Web of Science ®Google Scholar
• Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401
   PubMed Web of Science ®Google Scholar
• Loza E, Abásolo L, Jover JA, et al. Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. J Rheum 2008;35:159-65
   PubMed Web of Science ®Google Scholar
• Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403-14
   PubMed Web of Science ®Google Scholar
• West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheum 2005;24:117-22
   PubMed Web of Science ®Google Scholar
• Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004;13:283-98
   PubMed Web of Science ®Google Scholar
• Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis 2004;63:723-9
   PubMed Web of Science ®Google Scholar
• Aho K, Kaipiainen-Seppänen O, Heliövaara M, et al. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998;27:325-34
   PubMed Web of Science ®Google Scholar
• Puolakka K, Kautiainen H, Pohjolainen T, et al. Rheumatoid arthritis remains a threat to work productivity: a nationwide register based incidence study from Finland. Scand J Rheumatol 2010;39:436-8
   PubMed Web of Science ®Google Scholar
• Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheum 2002;29:62-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
   PubMed Web of Science ®Google Scholar
• Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105-12
   PubMed Web of Science ®Google Scholar
• Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheum 1992;19:1885-94
   Google Scholar
• Leirisalo-Repo M. Tulehduksellisten reumatautien uudet biologiset lääkkeet. Duodecim 2007;123:2459-67
   Google Scholar
• Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77
   PubMed Web of Science ®Google Scholar
• Barton GR, Briggs AH, Fenwick EAL. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886-97
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate. Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21
   PubMed Web of Science ®Google Scholar
• Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41
   PubMed Web of Science ®Google Scholar
• Laas K, Roine R, Räsänen P, et al. Health-related quality of life in patients with common rheumatic diseases referred to a university clinic. Rheum Int 2009;29:267-73
   PubMed Web of Science ®Google Scholar
• Laas K, Peltomaa R, Puolakka K, et al. Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice. Clin Exp Rheum 2009;27:315-20
   PubMed Web of Science ®Google Scholar
• Laas K, Peltomaa R, Kautiainen H, et al. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8
   PubMed Web of Science ®Google Scholar
• Paturi M, Tapanainen H, Reinivuo H, et al. Finravinto 2007 -tutkimus [The National FINDIET 2007 Survey]. Helsinki: National Public Health Institute, 2008
   Google Scholar
• Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 2009;48:436-9
   PubMed Web of Science ®Google Scholar
• Suomalaisen Lääkäriseuran Duodecimin ja Suomen Reumatologisen yhdistyksen asettama työryhmä. Nivelreuma. Helsinki: Käypä Hoito suositus, 2009
   Google Scholar
• National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. London: NICE TA130, 2007
   Google Scholar
• Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006;45:1167-9
   PubMed Web of Science ®Google Scholar
• Geborek P, Crnkic M, Petersson IF. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8
   PubMed Web of Science ®Google Scholar
• Bansback N, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Ducournau P, Wintfeld N, et al. Health Assessment Questionnaire-Disability Index Scores in patients with rheumatoid arthritis treated with tocilizumab plus conventional anti-rheumatic drugs. Value Health 2009;12:A434
   Google Scholar
• Brennan A, Bansback N, Reynolds A, et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94
   PubMed Web of Science ®Google Scholar
• Ducournau P, Kielhorn A, Wintfeld NS. Comparison of linear and nonlinear utility mapping between HAQ and EQ-5D using pooled data from the tocilizumab trials OPTION and LITHE. Rheumatology (Oxford) 2009;48(1 Suppl):i107-8
   Web of Science ®Google Scholar
• Boggs R, Sengupta N, Ashraf T. Estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7). Value Health 2002;5:452-3
   Google Scholar
• Hujanen T, Kapiainen S, Tuominen U, et al. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. Helsinki: Stakesin Työpapereita, 2008
   Google Scholar
• Kobelt G, Eberhardt K, Jönsson L, et al. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56
   PubMed Web of Science ®Google Scholar
• Hawthorne G, Buchbinder R, Defina J. Functional status and health-related Quality of Life Assessment in patients with rheumatoid arthritis. West Heidelberg: Monash University, 2000
   Google Scholar
• Hurst N, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis validity/responsiveness and reliability of EUROQOL (EQ-5D). Br J Rheumatol 1997;36:551-9
   PubMedGoogle Scholar
• Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-32
   PubMed Web of Science ®Google Scholar
• Virkki LM, Konttinen YT, Peltomaa R et al. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008;26:1059-66
   PubMed Web of Science ®Google Scholar
• Soini E. Incremental or average cost-utility of routine cataract surgery? Health Qual Life Outcomes 2006;4:74. http://www.hqlo.com/content/4/1/74/comments. Accessed September 30, 2009
   Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-229.
   Web of Science ®Google Scholar
• Davies A, Cifaldi MA, Segurado OG, et al. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009;36:16-26
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54
   PubMed Web of Science ®Google Scholar
• Tanno M, Nakamura I, Ito K, et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84
   PubMedGoogle Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-32
   PubMed Web of Science ®Google Scholar
• Tiippana-Kinnunen T, Laaksonen L, Kautiainen H, et al. Impact of early radiographic remission on the 15-year radiographic outcome in patients with rheumatoid arthritis. Scand J Rheumatol 2011;40:263-8
   PubMed Web of Science ®Google Scholar
• Immonen K, Finne P, Grönhagen-Riska C, et al. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid 2011;18:25-8
   PubMed Web of Science ®Google Scholar